Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor–Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action

Glück, Stefan

doi:10.1016/j.clbc.2013.10.008

Cited by 26 publications

(24 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5B, ER-positive or PR-positive patients tended to express low levels of CXCL2/8/13 and high levels of CXCL12/14 compared with ER-negative or PR-negative patients. ER-positive and PR-positive cancer cells depend on estrogen for their growth, so they can be treated with drugs to block estrogen effects (e.g., tamoxifen) and generally have a better prognosis [24]. Therefore, these results indicate that low expression of CXCL2/8/13 and high expression of CXCL12/14 may predict a better prognosis.…”

Section: Resultsmentioning

confidence: 99%

Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis

Chen

Qin

Peng

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Breast cancer is a common cause of cancer mortality throughout the world. The cross-talk between cancer cells and interstitial cells exerts significant effects on neoplasia and tumor development and is modulated in part by chemokines. CXC is one of four chemokine families involved in mediating survival, angiogenesis, and immunosensitization by chemoattracting leukocytes, and it incentivizes tumor cell growth, invasion and metastasis in the tumor microenvironment. However, the differential expression profiles and prognostic values of these chemokines remains to be elucidated. Methods: In this study, we compared transcriptional CXC chemokines and survival data of patients with breast carcinoma (BC) using the ONCOMINE dataset, Kaplan-Meier Plotter, TCGA and cBioPortal. Results: We discovered increased mRNA levels for CXCL8/10/11/16/17, whereas mRNA expression of CXCL1/2/3/4/5/6/7/12/14 was lower in BC patients compared to non-tumor tissues. Kaplan-Meier plots revealed that high mRNA levels of CXCL1/2/3/4/5/6/7/12/14 correlate with relapse-free survival (RFS) in all types of BC patients. Conversely, high CXCL8/10/11 predicted worse RFS in BC patients. Significantly, high transcription levels of CXCL9/12/13/14 conferred an overall survival (OS) advantage in BC patients, while high levels of CXCL8 demonstrated shorter OS in all BC sufferers. Conclusions: Integrative bioinformatics analysis suggests that CXCL8/12/14 are potential suitable targets for precision therapy in BC patients compared to other CXC chemokines.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis

Chen

Qin

Peng

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Evidence exists that ER+ MBC may either be unresponsive to ET (de novo resistance) or lose endocrine responsiveness by upregulating other signaling pathways involved in cell survival and proliferation (i.e., acquired endocrine resistance) . Several mechanisms may be responsible for acquired endocrine resistance, including downregulation or loss of ER expression, ER mutations generating mutant ER isoforms, or altered expression or activity of ER coregulators . Phosphorylation, methylation, ubiquitination, and additional posttranslational modifications of ER and its coregulators have been shown to influence ER activity and sensitivity to ET .…”

Section: Resultsmentioning

confidence: 99%

“…Preclinical data suggest that crosstalk between growth factor receptor and ER pathways may mediate the development of resistance to ET in ER+ MBC . Growth factor receptor pathways may act as ER‐independent drivers of tumor growth and survival, leading to the expression of ER‐target genes independently of estrogen binding to ER, therefore conferring resistance to ET . Epidermal growth factor receptor, HER2 epidermal growth factor receptor, and insulin growth factor receptor have been recognized as the most prominent factors contributing to endocrine resistance .…”

Section: Resultsmentioning

confidence: 99%

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer

Kaklamani

Gradishar

2017

The Oncologist

View full text Add to dashboard Cite

Metastatic breast cancer (MBC) results in substantial morbidity and mortality for women afflicted with this disease. A majority of MBCs are hormone-responsive and estrogen receptor-positive, making endocrine therapy (ET) an integral component of systemic therapy. With a primary goal of minimizing the effects of estrogen on hormone-responsive MBC, ETs are among the first targeted treatments that aim to inhibit the influence of estrogen receptor activation on tumor proliferation. Several biochemical mechanisms have been the focus of drug development for treatment, including selective estrogen-receptor modulation, aromatase inhibition, and selective estrogen-receptor degradation. Treatments that exploit these mechanisms have improved survival and quality of life for women with MBC. However, in many cases, resistance to ET limits their effectiveness. Elucidation of the complex cellular signal cascades involved in the development of acquired resistance to ET and the interrelationship of growth factor signaling and estrogen responsiveness have characterized components of these pathways as attractive targets for drug development. Based on these insights and with the aim of overcoming hormone resistance, targeted therapies are emerging as useful treatments for MBC. This article reviews current endocrine treatments of MBC as well as recent and ongoing study of combination treatments and targeted therapies that interfere with cellular proliferation pathways as means of overcoming resistance. 2017;22:507-517 IMPLICATIONS FOR PRACTICE: This review provides medical oncologists and other oncology health care providers with a current understanding of the rationale for endocrine therapy in estrogen receptor-positive metastatic breast cancer and the efficacy and safety profile of available treatment options. Additionally, current concepts regarding the development of treatment resistance and the treatment strategies for overcoming resistance are discussed. Enhancing the current information and the understanding of these topics will assist clinicians in evaluating optimal treatment options for their patients.

show abstract

“…Two phase III clinical trials exploring this issue in postmenopausal women in first-line treatment for MBC, using a combination of anastrozole and fulvestrant, produced diverging results [1 positive: SWOG 0226 [51] (HR (hazard ratio): 0.81; 95% confidence interval: 0.65-1.00), and 1 negative: Review articles: [102,103] Progressive disease without initial response to treatment…”

Section: Is There Evidence For Suggesting That a Combination Of Severmentioning

confidence: 99%

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

et al. 2020

View full text Add to dashboard Cite

Purpose Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on antiestrogen hormone therapy (HT). As consensus documents are valuable tools that assist in the decision-making process for establishing clinical strategies and optimize the delivery of health services, this consensus document has been created with the aim of developing recommendations on cretiera for hormone sensitivity and resistance in HER2-negative luminal MBC and facilitating clinical decision-making. Methods This consensus document was generated using a modification of the RAND/UCLA methodology, which included the definition of the project and identification of issues of interest, a non-exhaustive systematic review of the literature, an analysis and synthesis of the scientific evidence, preparation of recommendations, and external evaluation with a panel of 64 medical oncologists specializing in breast cancer. Results A Spanish panel of experts reached consensus on 32 of the 32 recommendations/conclusions presented in the first round and were accepted with an approval rate of 100% about definition of metastatic disease not susceptible to local curative treatment, definition of hormone sensitivity and hormone resistance in metastatic luminal disease and therapeutic decision-making. Conclusion We have developed a consensus document with recommendations on the treatment of patients with HER2negative luminal MBC that will help to improve therapeutic benefits.

show abstract

Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor–Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action

Cited by 26 publications

References 55 publications

Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis

Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Contact Info

Product

Resources

About